Mannose-modified erythrocyte membrane-coated Chuanmingshen violaceum polysaccharide PLGA nanoparticles to improve immune responses in mice

IF 4.8 2区医学 Q2 IMMUNOLOGY

International immunopharmacology Pub Date : 2025-03-12 DOI:10.1016/j.intimp.2025.114450

Shuyao Yang , Xinnan Zhang , Yao Wang , Jie Liu , Lu Wang , Yi Liao , Yanwen Yang , Tao Dai , Xuemei Yin , Shanshan Li , Lu Han , Jiangjiang Zhu , Haibo Feng

{"title":"Mannose-modified erythrocyte membrane-coated Chuanmingshen violaceum polysaccharide PLGA nanoparticles to improve immune responses in mice","authors":"Shuyao Yang , Xinnan Zhang , Yao Wang , Jie Liu , Lu Wang , Yi Liao , Yanwen Yang , Tao Dai , Xuemei Yin , Shanshan Li , Lu Han , Jiangjiang Zhu , Haibo Feng","doi":"10.1016/j.intimp.2025.114450","DOIUrl":null,"url":null,"abstract":"<div><div>This study developed a poly(lactic-<em>co</em>-glycolic acid) (PLGA) biomimetic nanoparticle (Man-RBC-CVPP) containing <em>Chuanmingshen violaceum</em> polysaccharide (CVP) and coated with a macrophage-targeting mannose receptor (DSPE-PEG-Man) modified RBCM. <em>In vitro</em> experiments demonstrated that Man-RBC-CVPP enhances antigen uptake and immune responses in RAW264.7 cells and can induce an immune response in mouse macrophages by activating the TLR4-mediated NF-κB signaling pathway. <em>In vivo</em> experiments showed that Man-RBC-CVPP promotes the activation of splenic dendritic cells (DCs) by increasing the expression of major histocompatibility complex class II (MHCII), CD80<sup>+</sup>, and CD86<sup>+</sup>. Further, it improves the maturation of splenic lymphocytes, increasing the expression of CD4<sup>+</sup> and CD8<sup>+</sup>. It also upregulates the secretion of cytokines, raises serum levels of the specific antibody IgG, and slows the release of OVA at the injection site. In summary, Man-RBC-CVPP can effectively enhance both cellular and humoral immune responses and provide controlled, long-term antigen release.</div></div>","PeriodicalId":13859,"journal":{"name":"International immunopharmacology","volume":"152 ","pages":"Article 114450"},"PeriodicalIF":4.8000,"publicationDate":"2025-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International immunopharmacology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1567576925004400","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

This study developed a poly(lactic-co-glycolic acid) (PLGA) biomimetic nanoparticle (Man-RBC-CVPP) containing Chuanmingshen violaceum polysaccharide (CVP) and coated with a macrophage-targeting mannose receptor (DSPE-PEG-Man) modified RBCM. In vitro experiments demonstrated that Man-RBC-CVPP enhances antigen uptake and immune responses in RAW264.7 cells and can induce an immune response in mouse macrophages by activating the TLR4-mediated NF-κB signaling pathway. In vivo experiments showed that Man-RBC-CVPP promotes the activation of splenic dendritic cells (DCs) by increasing the expression of major histocompatibility complex class II (MHCII), CD80⁺, and CD86⁺. Further, it improves the maturation of splenic lymphocytes, increasing the expression of CD4⁺ and CD8⁺. It also upregulates the secretion of cytokines, raises serum levels of the specific antibody IgG, and slows the release of OVA at the injection site. In summary, Man-RBC-CVPP can effectively enhance both cellular and humoral immune responses and provide controlled, long-term antigen release.

Abstract Image

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

International immunopharmacology 医学-免疫学

CiteScore

8.40

自引率

3.60%

发文量

935

审稿时长

53 days

期刊介绍： International Immunopharmacology is the primary vehicle for the publication of original research papers pertinent to the overlapping areas of immunology, pharmacology, cytokine biology, immunotherapy, immunopathology and immunotoxicology. Review articles that encompass these subjects are also welcome. The subject material appropriate for submission includes: • Clinical studies employing immunotherapy of any type including the use of: bacterial and chemical agents; thymic hormones, interferon, lymphokines, etc., in transplantation and diseases such as cancer, immunodeficiency, chronic infection and allergic, inflammatory or autoimmune disorders. • Studies on the mechanisms of action of these agents for specific parameters of immune competence as well as the overall clinical state. • Pre-clinical animal studies and in vitro studies on mechanisms of action with immunopotentiators, immunomodulators, immunoadjuvants and other pharmacological agents active on cells participating in immune or allergic responses. • Pharmacological compounds, microbial products and toxicological agents that affect the lymphoid system, and their mechanisms of action. • Agents that activate genes or modify transcription and translation within the immune response. • Substances activated, generated, or released through immunologic or related pathways that are pharmacologically active. • Production, function and regulation of cytokines and their receptors. • Classical pharmacological studies on the effects of chemokines and bioactive factors released during immunological reactions.